These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 26060392)
1. Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population. Basheer K; Mensah E; Khanam T; Minakaran N Clin Ophthalmol; 2015; 9():959-65. PubMed ID: 26060392 [TBL] [Abstract][Full Text] [Related]
2. What Effect Does Ethnicity Have on the Response to Ranibizumab in the Treatment of Wet Age-Related Macular Degeneration? Mohamed R; Gadhvi K; Mensah E Ophthalmologica; 2018; 240(3):157-162. PubMed ID: 29847823 [TBL] [Abstract][Full Text] [Related]
3. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: the TORPEDO trial at 2 years. Spielberg L; Leys A Graefes Arch Clin Exp Ophthalmol; 2010 Jul; 248(7):943-56. PubMed ID: 20204659 [TBL] [Abstract][Full Text] [Related]
4. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration. Gupta B; Adewoyin T; Patel SK; Sivaprasad S Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Heier JS; Brown DM; Chong V; Korobelnik JF; Kaiser PK; Nguyen QD; Kirchhof B; Ho A; Ogura Y; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Groetzbach G; Sommerauer B; Sandbrink R; Simader C; Schmidt-Erfurth U; Ophthalmology; 2012 Dec; 119(12):2537-48. PubMed ID: 23084240 [TBL] [Abstract][Full Text] [Related]
6. ROLE OF ADDITIONAL DEXAMETHASONE FOR THE MANAGEMENT OF PERSISTENT OR RECURRENT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION UNDER RANIBIZUMAB TREATMENT. Rezar-Dreindl S; Eibenberger K; Buehl W; Georgopoulos M; Weigert G; Krall C; Dunavoelgyi R; Schmidt-Erfurth U; Sacu S Retina; 2017 May; 37(5):962-970. PubMed ID: 27575409 [TBL] [Abstract][Full Text] [Related]
7. Fellow Eye Comparisons for 7-Year Outcomes in Ranibizumab-Treated AMD Subjects from ANCHOR, MARINA, and HORIZON (SEVEN-UP Study). Bhisitkul RB; Desai SJ; Boyer DS; Sadda SR; Zhang K Ophthalmology; 2016 Jun; 123(6):1269-77. PubMed ID: 26996339 [TBL] [Abstract][Full Text] [Related]
8. A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. Sivaprasad S; Patra S; DaCosta J; Adewoyin T; Shona O; Pearce E; Chong NV Ophthalmologica; 2011; 225(4):200-6. PubMed ID: 21293163 [TBL] [Abstract][Full Text] [Related]
9. Cataract surgery in ranibizumab-treated patients with neovascular age-related macular degeneration from the phase 3 ANCHOR and MARINA trials. Rosenfeld PJ; Shapiro H; Ehrlich JS; Wong P; Am J Ophthalmol; 2011 Nov; 152(5):793-8. PubMed ID: 21794843 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484 [TBL] [Abstract][Full Text] [Related]
11. Ranibizumab treatment outcomes in phakic versus pseudophakic eyes: an individual patient data analysis of 2 phase 3 trials. Weinberg DV; Shapiro H; Ehrlich JS Ophthalmology; 2013 Jun; 120(6):1278-82. PubMed ID: 23453513 [TBL] [Abstract][Full Text] [Related]
12. Combination photodynamic therapy and intravitreal ranibizumab in neovascular age-related macular degeneration in a North Indian population: a pilot study. Kumar A; Gopalakrishnan K; Sinha S Retina; 2008 Oct; 28(9):1296-301. PubMed ID: 18667951 [TBL] [Abstract][Full Text] [Related]
13. Driving ability reported by neovascular age-related macular degeneration patients after treatment with ranibizumab. Bressler NM; Chang TS; Varma R; Suñer I; Lee P; Dolan CM; Ward J; Ianchulev T; Fine J Ophthalmology; 2013 Jan; 120(1):160-8. PubMed ID: 23009891 [TBL] [Abstract][Full Text] [Related]
15. Five-year treatment outcomes following intravitreal ranibizumab injections for neovascular age-related macular degeneration in Japanese patients. Wada I; Oshima Y; Shiose S; Kano K; Nakao S; Kaizu Y; Yoshida S; Ishibashi T; Sonoda KH Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1411-1418. PubMed ID: 31119425 [TBL] [Abstract][Full Text] [Related]
16. Ranibizumab monotherapy versus single-session verteporfin photodynamic therapy combined with as-needed ranibizumab treatment for the management of neovascular age-related macular degeneration. Bashshur ZF; Schakal AR; El-Mollayess GM; Arafat S; Jaafar D; Salti HI Retina; 2011 Apr; 31(4):636-44. PubMed ID: 21124254 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration. Inoue M; Yamane S; Sato S; Sakamaki K; Arakawa A; Kadonosono K Am J Ophthalmol; 2016 Sep; 169():95-103. PubMed ID: 27320059 [TBL] [Abstract][Full Text] [Related]
18. LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. Ranchod TM; Ray SK; Daniels SA; Leong CJ; Ting TD; Verne AZ Retina; 2013 Sep; 33(8):1600-4. PubMed ID: 23549100 [TBL] [Abstract][Full Text] [Related]